Evolus (EOLS) Expected to Announce Quarterly Earnings on Wednesday

Evolus (NASDAQ:EOLS) will likely be issuing its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect the company to announce earnings of ($0.05) per share and revenue of $77.58 million for the quarter. Parties can check the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 4:30 PM ET.

Evolus Stock Down 2.6%

NASDAQ EOLS opened at $7.16 on Tuesday. Evolus has a 52 week low of $3.86 and a 52 week high of $9.31. The business’s fifty day simple moving average is $7.95 and its 200-day simple moving average is $6.27. The firm has a market cap of $472.92 million, a PE ratio of -13.77 and a beta of 1.33.

Analysts Set New Price Targets

Several research firms recently issued reports on EOLS. Wall Street Zen upgraded shares of Evolus from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th. HC Wainwright reaffirmed a “buy” rating and set a $13.00 target price on shares of Evolus in a research note on Tuesday, August 25th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Evolus in a report on Friday, September 11th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Evolus currently has an average rating of “Moderate Buy” and an average target price of $14.50.

Insider Buying and Selling

In other news, insider David Moatazedi sold 105,108 shares of the firm’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $9.04, for a total transaction of $950,176.32. Following the completion of the transaction, the insider directly owned 499,592 shares in the company, valued at $4,516,311.68. This trade represents a 17.38% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 5.00% of the stock is owned by company insiders.

About Evolus

Evolus, Inc is a commercial-stage medical aesthetics company focused on developing and marketing products for physicians and other licensed aesthetic providers. The company’s business is centered on minimally invasive treatments intended to address facial lines, wrinkles and other visible signs of aging.

Evolus’ primary product is Jeuveau (prabotulinumtoxinA-xvfs), an injectable botulinum toxin approved by the U.S. Food and Drug Administration for the temporary improvement of moderate to severe glabellar lines, commonly known as “frown lines,” in adults.